



**FDC Limited**

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

---

**Date:- August 07, 2025**

**To,**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

**BSE Script Code: 531599**

**National Stock Exchange of India Ltd.**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**NSE Symbol: FDC**

**Sub: Press Release on Q1 - FY 2025-26 Results.**

Dear Sir/Ma'am,

Please find attached herewith a Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2025.

Kindly take the same on record.

Thanking you,

Yours truly

**For FDC Limited**


**Varsharani Katre**

**Company Secretary & Compliance Officer**

**M No.: FCS-8948**

## FDC Limited reports Q1FY26 results

Mumbai, 7<sup>th</sup> Aug 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ended 30<sup>th</sup> June 2025.



### Consolidated Q1FY26 FDC reported

Rs. in crores	Q1FY26	Q1FY25	YoY Grw %
Operating Revenue	648	638	1.6%
EBITDA	140	147	-4.3%
EBITDA %	21.6%	23.0%	
PBT	160	163	-1.8%
PAT	121	119	1.9%
EPS (Rs.)	7.45	7.31	1.9%

### Commenting on the results;

We reported a stable performance in Q1FY26, with operating revenue of ₹648 crore, marking a moderate growth of 1.6% YoY. India formulation business showed a growth of 5.6% increase, Export formulation business was down by 33.8% YoY and API business showed growth of 3.3% YoY.

The US business shows good signs of recovery as the past challenges of recall related issues and revisions in API impurities standard by FDA are now addressed and business has shown good momentum with revenue of INR 11.6 cr from supplies made during Q1FY26, reflecting a 106% YoY growth. However, overall revenue of US business is down by 22.2% YoY

**CORPORATE OFFICE** : C - 11 & 12, Dalia Industrial Estate, Oshiwara Village, Off. Link Road, Near Fun Republic, Andheri (W), Mumbai - 400 053.  
Tel.: +91-22-6910 7100  
E-mail: [fdc@fdcindia.com](mailto:fdc@fdcindia.com) Website: [www.fdcindia.com](http://www.fdcindia.com)

**REGISTERED OFFICE** : B-8, M.I.D.C Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 Fax: 0240-255 4299  
E-mail: [waluj@fdcindia.com](mailto:waluj@fdcindia.com) CIN: L24239MH1940PLC003176

primarily due to lower profit share from the US partners in view of lower sales during FY 25, which was affected by recall-related issues and pending clarification from FDA regarding impurity standards of the API used in the formulation. The FDA has now issued the clarification on impurities standards and supplies have now resumed. Emerging market business was down by 39% YoY with revenue of INR 26 cr. This downward trend is primarily due to supply challenges and therefore, some of the orders shifted to Q2FY26. The order pipeline is healthy, and management expects to address the supplies challenges in coming quarters. API business showed moderate revenue growth of 3.3% YoY with revenue of INR 26 cr.

Our EBITDA stood at ₹140 crore, with margins at 21.6% compared to 23.0% last year. EBITDA is down majorly due to certain strategic expenditure incurred for future business growth particularly higher Research and Development expenses grew by 271.4% YoY with costs of INR 8.5 cr and higher employee costs for moderate expansion of field force and incremental manpower for ORS manufacturing capacity expansion at the plants.

## Business-wise Sales Performance

₹ Cr	Q1FY26	YoY Grw %
Net Sales	648	1.6%
India Formulations	579	5.6%
US Formulations	16	-22.2%
Emerging Markets	26	-39.3%
API Sales	26	3.3%

## India Market:

The sale of branded formulations in India for Q1FY26 was Rs. 579 crores, with a growth of 5.6% on YoY and 39.7% on QoQ. Overall sales in the Indian market accounted for 90% of total consolidated sales for the quarter.

As per secondary sales data by IQVIA for MAT June 30, 2025, the Company delivered growth of 10.8% compared to the Indian Pharmaceutical Market (IPM) growth of 8.0% YoY.

**CORPORATE OFFICE** : C - 11 & 12, Dalia Industrial Estate, Oshiwara Village, Off. Link Road, Near Fun Republic, Andheri (W), Mumbai - 400 053.  
Tel.: +91-22-6910 7100  
E-mail: [fdc@fdcindia.com](mailto:fdc@fdcindia.com) Website: [www.fdcindia.com](http://www.fdcindia.com)

**REGISTERED OFFICE** : B-8, M.I.D.C Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 Fax: 0240-255 4299  
E-mail: [waluj@fdcindia.com](mailto:waluj@fdcindia.com) CIN: L24239MH1940PLC003176

Electral has moved up to 14<sup>th</sup> in IPM in MAT Jun'25 as compared to 18<sup>th</sup> in the same period last year. Electral is the fastest growing product among the Top 20 products of IPM in MAT Jun-24 and has become 1<sup>st</sup> brand at FDC limited to reach milestone of Rs. 600 crores brand in IPM.

### **Export Formulations Market:**

Formulation Sales in the Export market were Rs. 42 crores in Q1FY26, down by 33.8% over YoY and lower by 8.5% over QoQ and accounted for 6% of total consolidated sales.

### **API Business:**

API Sales were Rs. 26 crores in Q1FY26, up by 3.3% over YoY and lower by 14.3% over QoQ and accounted for 4% of total consolidated sales.

### **ABOUT FDC LTD**

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

### **Disclaimer**

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

---

**CORPORATE OFFICE** : C - 11 & 12, Dalia Industrial Estate, Oshiwara Village, Off. Link Road, Near Fun Republic, Andheri (W), Mumbai - 400 053.  
Tel.: +91-22-6910 7100  
E-mail: [fdc@fdcindia.com](mailto:fdc@fdcindia.com) Website: [www.fdcindia.com](http://www.fdcindia.com)

**REGISTERED OFFICE** : B-8, M.I.D.C Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 Fax: 0240-255 4299  
E-mail: [waluj@fdcindia.com](mailto:waluj@fdcindia.com) CIN: L24239MH1940PLC003176